Winner Medical Public Company Limited, or WINMED, presented the INTERCEPT™ Blood System at the Hospital Blood Bank 2026 academic conference to enhance blood safety before it is used to treat patients. This pathogen inactivation technology can directly inhibit and destroy pathogens in blood components, reducing the risk of transfusion-transmitted infections and aligning with the public health trend that emphasizes proactive risk prevention. Having an internationally recognized product strengthens WINMED's competitive edge as a provider of high-value-added medical solutions, particularly in the blood service medicine segment, which has high barriers to market entry. Participation in this event also reflects the company's role in driving innovation into the country's blood service system and building collaborative networks with medical professionals.
Winnergy Medical Public Company LimitedPresenting INTERCEPT Blood System showcases innovative pathogen inactivation technology, enhancing competitive edge in high-barrier blood service segment.